[English]  [Pусский]  [中文]  
 
ctt-journal > Shumilov et al. (Abstract)

Shumilov et al. (Abstract)

Cellular Therapy and Transplantation (CTT), Vol. 3, No. 12
doi: 10.3205/ctt-2011-No12-abstract45

© The Authors. This abstract is provided under the following license: Creative Commons Attribution 3.0 Unported

Abstract accepted for "5th Raisa Gorbacheva Memorial Meeting Hematopoietic Stem Cell Transplantation in Children and Adults", Saint Petersburg, Russia, September 18–20, 2011

Preliminary Program

Contribute a comment

 

Minimal residual disease evaluation in patients with acute lymphoblastic leukemia treated with chemotherapy and allogeneic hematopoietic stem cell transplantation

Evgeniy G. Shumilov, Alexandra A. Sipol, Elena V. Babenko, Elena V. Semenova, Ludmila S. Zubarovskaya, Boris V. Afanasyev

R.M. Gorbacheva Memorial Institute of Children Hematology and Transplantation, St. Petersburg Pavlov State Medical University, St. Petersburg, Russia

Correspondence: Alexandra A. Sipol, R.M. Gorbacheva Memorial Institute of Children Hematology and Transplantation, St. Petersburg Pavlov State Medical University, 6/8 Tolstoy str., Saint-Petersburg, 197022, Russia, E-mail: transimmun@spam is badmail.ru

Abstract

The aim of this study was to define the prognostic value of minimal residual disease (MRD) detection by flow cytometry in patients with ALL who had undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Materials and methods: In the current study 103 patients with acute lymphoblastic leukemia (ALL) were investigated. Most opatients had B-cell ALL (94), and 9 patients had T-cell ALL. Fifty-one patients (median age 8 years) were treated with chemotherapy, and 52 patients (median age 11 years) underwent allo-HSCT. A total of 324 samples of bone marrow were analyzed by flow cytometry. The following monoclonal antibody combinations were used: CD10/CD34/CD19/CD45, CD22/CD34/CD19/CD45, CD38/CD34/CD19/CD45, CD7/CD5/CD45/CD3, and CD7/CD2/CD45/CD3. To verify the MRD-status we compared the flow cytometry data with molecular biology, clinical, and morphology data.

Results: Seventeen patients, treated with chemotherapy, who had negative MRD during all periods of observation, demonstrated a persistent remission. The incidence of relapse in patients with more than one positive MRD was significantly higher (p=0.001) than in patients with a negative MRD. The incidence of relapse was significantly higher in patients with a positive MRD before and after allo-HSCT (p=0.043, p=0.014) in comparison with the group of patients demonstrating a negative MRD status. According to our investigation the threshold level of MRD influenced on prognosis of the disease was 2.5*10(-4).

Conclusion: The persistence of cells with leukemia-associated immunophenotype in patients with ALL is an unfavorable prognostic factor of relapse; developing both after chemotherapy and allo-HSCT. 

Keywords: ALL, MRD, flow cytometry, relapse, allo-HSCT, prognosis